Compare EPSN & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPSN | ARMP |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.2M | 199.7M |
| IPO Year | 2018 | 1996 |
| Metric | EPSN | ARMP |
|---|---|---|
| Price | $5.16 | $3.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.50 |
| AVG Volume (30 Days) | 56.9K | ★ 83.8K |
| Earning Date | 11-20-2026 | 11-20-2026 |
| Dividend Yield | ★ 4.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.20 | $2.75 |
| 52 Week High | $6.65 | $14.98 |
| Indicator | EPSN | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 26.68 | 55.86 |
| Support Level | N/A | $3.38 |
| Resistance Level | $6.01 | $3.96 |
| Average True Range (ATR) | 0.24 | 0.37 |
| MACD | -0.14 | 0.08 |
| Stochastic Oscillator | 1.84 | 93.33 |
Epsilon Energy Ltd is a North American on-shore focused independent natural gas and oil company engaged in the acquisition, development, gathering and production of natural gas and oil reserves. Its properties include Appalachian Basin-Pennsylvania, Permian Basin-Texas and New Mexico, Anadarko Basin-Oklahoma, Powder River Basin-Wyoming, Western Canadian Sedimentary Basin-Alberta, Canada. Its segments include The Upstream segment activities include acquisition, development and production of natural gas and oil reserves on properties within the United States and Canada; and The Gas Gathering segment partners with two other companies to operate a natural gas gathering system. The Upstream segment derives the majority of the revenue.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.